GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » YoY EBITDA Growth

ABL Bio (XKRX:298380) YoY EBITDA Growth : -144.06% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ABL Bio YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. ABL Bio's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -144.06%.

ABL Bio's EBITDA per Share for the three months ended in Mar. 2024 was ₩-236.45.

ABL Bio YoY EBITDA Growth Historical Data

The historical data trend for ABL Bio's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio YoY EBITDA Growth Chart

ABL Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial 79.28 -48.88 24.16 116.27 -69.62

ABL Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 416.58 -430.91 -109.92 26.12 -144.06

ABL Bio YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

ABL Bio's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(43.51-143.233)/ | 143.233 |
=-69.62 %

ABL Bio's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-236.446-536.613)/ | 536.613 |
=-144.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABL Bio YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of ABL Bio's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Bio (XKRX:298380) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » YoY EBITDA Growth
Comparable Companies
XKRX:064550 XKRX:016790 XKRX:085660 XKRX:096530 XKRX:005250 XKRX:950160 XKRX:950210 XKRX:087010 XKRX:141080 XKRX:310210 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488
Website
https://www.ablbio.com
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio (XKRX:298380) Headlines

No Headlines